More about

Clinical Trials

News
May 17, 2023
2 min read
Save

Changes to primary endpoints of phase 3 cancer trials common but ‘markedly underreported’

Changes to primary endpoints of phase 3 cancer trials common but ‘markedly underreported’

Primary endpoints of randomized clinical trials for cancer therapies frequently change after trial initiation, according to findings published in JAMA Network Open.

News
May 16, 2023
1 min read
Save

Tributyrin linked to improved motor symptoms, inflammatory markers in Parkinson’s

Tributyrin linked to improved motor symptoms, inflammatory markers in Parkinson’s

CHICAGO — Tributyrin supplementation may have a beneficial effect on motor symptoms and inflammatory markers in Parkinson’s disease, according to data at the International Association of Parkinsonism and Related Disorders World Congress.

News
May 15, 2023
2 min read
Save

Continuous subcutaneous apomorphine infusion reduces motor fluctuations in PD

Continuous subcutaneous apomorphine infusion reduces motor fluctuations in PD

CHICAGO — Continuous subcutaneous apomorphine infusion reduced “off” time and increased “on” time without troublesome dyskinesia in patients with Parkinson’s disease in the United States, with no new safety signals reported.

News
May 14, 2023
2 min read
Save

Huntington Disease Health Index accurate for patient-reported changes in symptom burden

Huntington Disease Health Index accurate for patient-reported changes in symptom burden

CHICAGO – The Huntington Disease Health Index was an accurate, clinically meaningful tool for participants in the KINECT-HD trial to report symptomatic disease burden changes when treated with valbenazine, according to a recent study.

News
May 10, 2023
3 min watch
Save

VIDEO: Two-thirds of MS patients on ocrelizumab had no disease activity for 4 years

VIDEO: Two-thirds of MS patients on ocrelizumab had no disease activity for 4 years

BOSTON — The majority of patients with relapsing-remitting MS who took ocrelizumab had no evidence of disease activity for 4 years, according to a study presented at the American Academy of Neurology annual meeting.

News
May 09, 2023
2 min read
Save

Leqembi reduced biomarkers of Alzheimer’s, slowed cognitive decline at 18 months

Leqembi reduced biomarkers of Alzheimer’s, slowed cognitive decline at 18 months

BOSTON — Treatment with Leqembi reduced markers of amyloid and tau in patients with early Alzheimer’s disease and slowed cognitive and functional decline at 18 months, according to data at the American Academy of Neurology annual meeting.

News
May 08, 2023
1 min read
Save

Vyvgart well-tolerated, improved clinical outcomes in generalized myasthenia gravis

Vyvgart well-tolerated, improved clinical outcomes in generalized myasthenia gravis

BOSTON — Long-term treatment with Vyvgart was safe, well-tolerated and effective in reducing immunoglobulin G antibody levels and improving clinical outcomes in patients with generalized myasthenia gravis.

News
May 05, 2023
2 min read
Save

Enrollment criteria for multiple myeloma trials may exclude racial, ethnic minorities

Enrollment criteria for multiple myeloma trials may exclude racial, ethnic minorities

Parameters established to determine who can enroll in clinical trials for new multiple myeloma treatments may contribute to underrepresentation of certain racial and ethnic minorities, according to data published in Blood.

News
May 04, 2023
2 min read
Save

Combination pramipexole, rasagiline reduced daytime sleepiness in adults with early PD

Combination pramipexole, rasagiline reduced daytime sleepiness in adults with early PD

BOSTON — Treatment with an investigational combination of low-dose pramipexole and rasagiline led to less excessive daytime sleepiness and fewer adverse events compared with pramipexole alone in early Parkinson’s disease, research showed.

News
May 03, 2023
2 min read
Save

AAK1 inhibitor shows promise as treatment for peripheral neuropathic pain

AAK1 inhibitor shows promise as treatment for peripheral neuropathic pain

BOSTON — Treatment with LX9211 reduced pain related to postherpetic neuralgia and may be a valuable addition to current options for peripheral neuropathic pain, according to a presenter at the American Academy of Neurology annual meeting.

View more